Last reviewed · How we verify
Radiolabeled EDG-5506 Intravenous — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Radiolabeled EDG-5506 Intravenous (Radiolabeled EDG-5506 Intravenous) — Edgewise Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Radiolabeled EDG-5506 Intravenous TARGET | Radiolabeled EDG-5506 Intravenous | Edgewise Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Radiolabeled EDG-5506 Intravenous CI watch — RSS
- Radiolabeled EDG-5506 Intravenous CI watch — Atom
- Radiolabeled EDG-5506 Intravenous CI watch — JSON
- Radiolabeled EDG-5506 Intravenous alone — RSS
Cite this brief
Drug Landscape (2026). Radiolabeled EDG-5506 Intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/radiolabeled-edg-5506-intravenous. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab